Illumina, Inc. (ILMN): Price and Financial Metrics


Illumina, Inc. (ILMN): $432.82

-0.38 (-0.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ILMN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

ILMN POWR Grades


  • Quality is the dimension where ILMN ranks best; there it ranks ahead of 95.6% of US stocks.
  • The strongest trend for ILMN is in Growth, which has been heading up over the past 48 weeks.
  • ILMN's current lowest rank is in the Sentiment metric (where it is better than 40.33% of US stocks).

ILMN Stock Summary

  • Illumina Inc's market capitalization of $63,550,440,000 is ahead of 95.85% of US-listed equities.
  • With a one year PEG ratio of 2,947.1, Illumina Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 98.76% of US stocks.
  • The price/operating cash flow metric for Illumina Inc is higher than 92.18% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Illumina Inc are VMW, ADSK, DXCM, ATVI, and ANSS.
  • ILMN's SEC filings can be seen here. And to visit Illumina Inc's official web site, go to www.illumina.com.

ILMN Valuation Summary

  • In comparison to the median Healthcare stock, ILMN's EV/EBIT ratio is 133.79% higher, now standing at 68.5.
  • Over the past 243 months, ILMN's price/sales ratio has gone down 111.2.
  • ILMN's price/sales ratio has moved down 111.2 over the prior 243 months.

Below are key valuation metrics over time for ILMN.

Stock Date P/S P/B P/E EV/EBIT
ILMN 2021-08-31 16.9 12.9 87.3 68.5
ILMN 2021-08-30 16.9 12.9 87.3 68.5
ILMN 2021-08-27 17.2 13.2 88.7 69.7
ILMN 2021-08-26 17.4 13.3 89.9 70.7
ILMN 2021-08-25 18.0 13.8 93.1 73.2
ILMN 2021-08-24 17.7 13.6 91.6 72.0

ILMN Growth Metrics

  • The year over year net cashflow from operations growth rate now stands at -4.67%.
  • The 4 year cash and equivalents growth rate now stands at 163.74%.
  • Its 5 year price growth rate is now at 105.51%.
ILMN's revenue has moved up $1,541,390,000 over the prior 52 months.

The table below shows ILMN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 3,966 1,094 768
2021-03-31 3,473 1,081 630
2020-12-31 3,239 1,080 656
2020-09-30 3,238 1,117 638
2020-06-30 3,351 1,231 693
2020-03-31 3,556 1,134 942

ILMN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ILMN has a Quality Grade of A, ranking ahead of 95.45% of graded US stocks.
  • ILMN's asset turnover comes in at 0.489 -- ranking 48th of 75 Measuring and Control Equipment stocks.
  • TRMB, AMOT, and PBIO are the stocks whose asset turnover ratios are most correlated with ILMN.

The table below shows ILMN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-04 0.489 0.686 0.187
2021-04-04 0.448 0.676 0.175
2021-01-03 0.439 0.680 0.173
2020-09-27 0.443 0.690 0.165
2020-06-28 0.464 0.703 0.174
2020-03-29 0.497 0.704 0.209

ILMN Price Target

For more insight on analysts targets of ILMN, see our ILMN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $459.00 Average Broker Recommendation 1.92 (Hold)

ILMN Stock Price Chart Interactive Chart >

Price chart for ILMN

ILMN Price/Volume Stats

Current price $432.82 52-week high $555.77
Prev. close $433.20 52-week low $279.88
Day low $427.10 Volume 811,900
Day high $436.95 Avg. volume 910,090
50-day MA $477.38 Dividend yield N/A
200-day MA $429.97 Market Cap 63.49B

Illumina, Inc. (ILMN) Company Bio


Illumina is a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. The company's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company was founded in 1998 and is based in San Diego, California.


ILMN Latest News Stream


Event/Time News Detail
Loading, please wait...

ILMN Latest Social Stream


Loading social stream, please wait...

View Full ILMN Social Stream

Latest ILMN News From Around the Web

Below are the latest news stories about Illumina Inc that investors may wish to consider to help them evaluate ILMN as an investment opportunity.

Sample Preparation Global Market Report 2021: COVID-19 Implications And Growth

Major players in the sample preparation market are Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, Illumina, Qiagen NV, PerkinElmer, F Hoffman La Roche, Tecan Group Ltd. , Hamilton Company, Norgen Biotek Corporation, Waters Corporation, Promega Corporation, and Biotage AB. Major players in the sample preparation market are Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, Illumina, Qiagen NV, PerkinElmer, F Hoffman La Roche, Tecan Group Ltd. , Hamilton Company, Norgen Biotek Corporation, Waters Corporation, Promega Corporation, and Biotage AB.

Intrado Digital Media | September 24, 2021

Biological Chip Market Evolve in Near Future | Abbott, Agilent Technologies, Illumina, PerkinElmer

The Biological Chip market research report added by Report Ocean, is an in-depth analysis of the latest developments, market size, status, upcoming technologies, industry drivers, challenges, regulatory policies, with key company profiles and strategies of players. The research study []

iCrowdNewswire | September 23, 2021

Illumina/GRAIL: Testing Vestagers effort to expand EU merger control

The controversial $7.1 billion acquisition of GRAIL by Illumina is developing into a test of the European Commissions new guidance on merger control, but also of the EU''s competition chief Margrethe Vestager''s resolve to expand the bloc''s supervision of such mergers.

EURACTIV | September 22, 2021

Genotyping Market may see a big move by 2027 | Illumina, Affymetrix, Life Technologies, Agilent Technologies, Qiagen

Genotyping Market forecast to 2027 The Global Genotyping Market report provides information about the Global industry, including valuable facts and figures. This research study explores the Global Market in detail such as industry chain structures, raw material suppliers, with manufacturing The Genotyping Sales market examines the primary segments of the scale of the market. This []

Cheshire Media | September 22, 2021

Genomics Market 2020, Share, Size, Research Report, Growth Trends, Revenue, Segmentation | Companies like ILLUMINA, AGILENT TECHNOLOGIES, THERMO FISHER SCIENTIFIC, EUROFINS SCIENTIFIC, QIAGEN

Genomics Market Scenario 2020-2027: The Global Genomics market exhibits comprehensive information that is a valuable source of insightful data for business strategists during the decade 2014-2027. On the basis of historical data, Genomics market report provides key segments and their sub-segments, revenue and demand & supply data. Considering technological breakthroughs of the market Genomics industry []

Cheshire Media | September 21, 2021

Read More 'ILMN' Stories Here

ILMN Price Returns

1-mo -8.08%
3-mo -8.81%
6-mo 9.57%
1-year 44.33%
3-year 19.75%
5-year 142.52%
YTD 16.98%
2020 11.53%
2019 10.61%
2018 37.27%
2017 70.64%
2016 -33.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.8893 seconds.